← All trials
NCT01848106
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2013
- Primary completion
- Aug 1, 2014
- Completion date
- Aug 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 3232
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Regado BiosciencesLead sponsor
- University of RochesterOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- Regado BiosciencesStudy director
- ParexelCollaborator
- University of RochesterCollaborator
- Canadian VIGOUR CentreCollaborator
- Duke UniversityCollaborator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.